Please visit our booth to learn more about the Value of Treatment case study on Alzheimers and pick up your brand new extended publication of the Alzheimers case study findings or download it HERE.

Alzheimer’s disease (AD) is a progressive disorder that spans over many years, in other words: the brain
starts deteriorating years before symptoms emerge. When are affected people becoming “patients” across
the spectrum of AD and what can we do about it? Between the early signs of being affected by AD and the
ability to provide treatment, many years will pass and many things could have been done. Amidst the call for
early intervention and putting knowledge and resources in the hands of patients and care givers, we are still
faced with a number of societal, ethical, technical and medical challenges. These are the premises of our
lunch session, where we would like to discuss the concept of “early intervention” across its many facets and
develop a new understanding of AD.

In this short session, experts and stakeholders will present the scientific rationale for this new understanding
of Alzheimer’s disease and the ethical challenges it holds; explore the opportunities to monitor and control
the risk factors through eHealth interventions; and to assess the potential socio-economic impact of treating
AD before the onset of dementia.

Speakers include:

Moderator: Donna Walsh (EFNA)
SS4.1. Nilsy Desaint (MSD): Would You Want to Know If You’ll Get Alzheimer’s?
SS4.2. Dr. Alex Milton (University of Southampton): eHealth interventions to prevent dementia
SS4.3 Dr. Ron Handels (University of Maastricht): The value of treating Alzheimer’s disease before the onset of dementia

The post EBC at 27th Alzheimer Europe Conference appeared first on European Brain Council (EBC).